A new category stent with novel polyphosphazene surface modification
dc.contributor.author | Mori, H. | |
dc.contributor.author | Jinnouchi, H. | |
dc.contributor.author | Diljon, C. | |
dc.date.accessioned | 2019-06-05T18:28:12Z | |
dc.date.available | 2019-06-05T18:28:12Z | |
dc.date.issued | 2018 | |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048968939&doi=10.2217%2ffca-2017-0103&partnerID=40&md5=32a19e81bc76978b92766305a262d236 | |
dc.identifier.uri | http://hdl.handle.net/10713/9386 | |
dc.description.abstract | The COBRA-PzF™ (CeloNova BioSciences, Inc., TX, USA) is a new type of coronary stent composed of a cobalt chromium metallic backbone surrounded by a nanothin layer of Polyzene-F (PzF) without any added drug. Evidence from basic studies supports antithrombotic and anti-inflammatory properties for the PzF surface coating. Preclinical studies support the thromboresistance of PzF-coated surfaces and clinical studies have shown good outcomes for patients receiving this device with very low rates of stent thrombosis. COBRA-PzF may be especially useful in patients at high risk for bleeding. Ongoing clinical trials will determine whether shortening the duration of dual antiplatelet therapy to less than 1 month is feasible and these data may represent a new paradigm with regards to patients at high risk for bleeding. Copyright 2018 Future Medicine Ltd. | en_US |
dc.description.uri | https://dx.doi.org/10.2217/fca-2017-0103 | en_US |
dc.language.iso | en-US | en_US |
dc.publisher | Future Medicine Ltd. | en_US |
dc.relation.ispartof | Future Cardiology | |
dc.subject | bleeding | en_US |
dc.subject | drug-eluting stent | en_US |
dc.subject | polymer | en_US |
dc.subject | stent | en_US |
dc.subject | stent thrombosis | en_US |
dc.title | A new category stent with novel polyphosphazene surface modification | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.2217/fca-2017-0103 | |
dc.identifier.pmid | 29582698 |